Open Access

ARTICLE

Tadalafil: a new agent for erectile dysfunction

Gerald B. Brock

Department of Surgery, Division of Urology, St. Joseph’s Health Centre, London, Ontario, Canada
Address correspondence to Dr. Gerald B. Brock, St. Joseph’s Health Centre, 268 Grosvenor Street, Urology Department, London, ON N6A 4V2 Canada

Canadian Journal of Urology 2003, 10(Suppl.1), 17-22.

Abstract

Oral phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction are preferred by most men, and are recommended in guidelines as first-line therapy, because of convenience, high efficacy, and low rates of side effects. Tadalafil (Cialis™) is a new agent that has been studied in different patient populations. It has a different molecular structure than other PDE5 inhibitors, and a different pharmacologic profile that provides a longer period of effectiveness than other agents. This article will review clinical trials on tadalafil, to provide a comprehensive overview of its efficacy and safety.

---

Keywords

---